Skip to main content

Advertisement

Log in

Results and outcomes after endoscopic treatment of upper urinary tract carcinoma: the Austrian experience

  • Topic paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Introduction

Through evolution in technology, endoscopic treatment has gained popularity for the treatment of upper tract urothelial carcinoma (ENDO-UTUC).

Methods

A total of 20 patients with ENDO-UTUC were compared to 178 treated by radical nephroureterectomy (RNU) for a pTa-1 UTUC, and a systematic review was performed.

Results

Mean age for ENDO-UTUC was 71.9 ± 16.0 years, and tumor features were favorable (90 % papillary, 14 low grade, 11 pTa). All ENDO-UTUC were performed ureteroscopically. Mean follow-up was 20.4 ± 30 months. The 5-year overall survival (OS) rate was 45 %. Local (LR) and bladder recurrence (BR) was 25 and 15 %. Time to definitive treatment was longer, ASA higher, LR rates higher, OS lower for ENDO-UTUC (all p < 0.001), but no difference was recorded for BR (p = 0.056) and cancer-specific survival (CSS) (p = 0.364). Postoperative kidney function (KF) was better in the ENDO-UTUC (p = 0.048), though preoperative KF showed no difference. The maximal level of evidence was 3b, patients were highly selected, numbers of patients were low, and ASA scores high. OS was rather low and CSS high. LR rate was high (61 %) and BR rate moderate (39 %) for ureteroscopic and 36 and 28 %, respectively, for percutaneous approach.

Conclusions

LR for ENDO-UTUC is high. In high-grade UTUC, oncological outcome is worse. RNU is associated with a significant loss of KF, but LR is rare. ENDO-UTUC is reserved for selected cases if elective. In imperative cases, it has to be balanced between KF, morbidity of the procedure, risk of operation and tumor control. ENDO-UTUC is not necessarily underused in Austria, because of lack in evidence, but 41 % of all RNU were performed in pTa/pTis/pT1 lesions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Munoz JJ, Ellison LM (2000) Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol 164(5):1523–1525

    Article  PubMed  CAS  Google Scholar 

  2. Rouprêt M, Zigeuner R, Palou J, Boehle A, Kaasinen E, Sylvester R, Babjuk M, Oosterlinck W (2011) European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol 59(4):584–594

    Article  PubMed  Google Scholar 

  3. Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD, Wood CG, Collaboration UTUCCUTUC (2009) Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer 115(6):1224–1233

    Article  PubMed  Google Scholar 

  4. Kaag MG, O’Malley RL, O’Malley P et al (2010) Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol 58(4):581–587

    Article  PubMed  Google Scholar 

  5. Zhang QL, Rothenbacher D (2008) „Prevalence of chronic kidney disease in population-based studies: systematic review”. BMC public health 8:117

    Article  PubMed  Google Scholar 

  6. USRDS (2010) United States Renal Data System 2010 Annual Data Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD http://www.usrds.org/2010/pdf/v1_04.pdf

  7. Cutress ML, Stewart GD, Wells-Cole S, Phipps S, Thomas BG, Tolley DA (2012) Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience. BJU Int. doi:10.1111/j.1464-410X.2012.11169.x

    Google Scholar 

  8. Grasso M, Fishman AI, Cohen J, Alexander B (2012) Ureteroscopic and extirpative treatment of upper urinary tract urothelial carcinoma: a 15-year comprehensive review of 160 consecutive patients. BJU Int doi. doi:10.1111/j.1464-410X.2012.11066.x

    Google Scholar 

  9. Gadzinski AJ, Roberts WW, Faerber GJ, Wolf JS (2010) Long-term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma. J Urol 183(6):2148–2153

    Article  PubMed  Google Scholar 

  10. Cornu JN, Rouprêt M, Carpentier X, Geavlete B, de Medina SG, Cussenot O, Traxer O (2010) Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. World J Urol 28(2):151–156

    Article  PubMed  Google Scholar 

  11. Pak RW, Moskowitz EJ, Bagley DH (2009) What is the cost of maintaining a kidney in upper-tract transitional-cell carcinoma? An objective analysis of cost and survival. J Endourol 23(3):341–346

    Article  PubMed  Google Scholar 

  12. Lucas SM, Svatek RS, Olgin G, Arriaga Y, Kabbani W, Sagalowsky AI, Lotan Y (2008) Conservative management in selected patients with upper tract urothelial carcinoma compares favourably with early radical surgery. BJU Int 102:172–176

    Article  PubMed  Google Scholar 

  13. Painter DJ, Denton K, Timoney AG, Keeley FX (2008) Ureteroscopic management of upper-tract urothelial cancer: an exciting nephron-sparing option or an unacceptable risk? J Endourol 22(6):1237–1239

    Article  PubMed  Google Scholar 

  14. Krambeck AE, Thompson RH, Lohse CM, Patterson DE, Segura JW, Zincke H, Elliott DS, Blute ML (2007) Endoscopic management of upper tract urothelial carcinoma in patients with a history of bladder urothelial carcinoma. J Urol 177(5):1721–1726

    Article  PubMed  Google Scholar 

  15. Reisiger K, Hruby G, Clayman and Landman RV, Landman J (2007) Office-based surveillance ureteroscopy after endoscopic treatment of transitional cell carcinoma: technique and clinical outcome. Urology 70:263–266

    Article  PubMed  Google Scholar 

  16. Rouprêt M, Hupertan V, Traxer O, Loison G, Chartier-Kastler E, Conort P, Bitker MO, Gattegno B, Richard F, Cussenot O (2006) Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma. Urology 67(6):1181–1187

    Article  PubMed  Google Scholar 

  17. Johnson GB, Fraiman M, Grasso M (2005) “Broadening experience with the retrograde endoscopic management of upper urinary tract urothelial malignancies. B JU Int 95(Suppl.2):110–113

    Google Scholar 

  18. Iborra I, Solsona E, Casanova J, Ricós JV, Rubio J, Climent MA (2003) Conservative elective treatment of upper urinary tract tumors: a multivariate analysis of prognostic factors for recurrence and progression. J Urol 169(1):82–85

    Article  PubMed  CAS  Google Scholar 

  19. Matsuoka K, Lida S, Tomiyasu K, Inoue M, Noda S (2003) Transurethral endoscopic treatment of upper urinary tract tumors using a holmium: YAG laser. Lasers Surg Med 32:336–340

    Article  PubMed  Google Scholar 

  20. Daneshmand S, Quek ML, Huffman JL (2003) Endoscopic management of upper urinary tract transitional cell carcinoma:long-term experience. Cancer 98:55–60

    Article  PubMed  Google Scholar 

  21. Engelmyer EI, Belis JA (1996) Long-term ureteroscopic management of low-grade transitional cell carcinoma of the upper urinary tract. Tech Urol 2(2):113–116

    PubMed  CAS  Google Scholar 

  22. Gaboardi F, Bozzola A, Dotti E, Galli L (1994) Conservative treatment of upper urinary tract tumors with Nd: YAG laser. J Endourol 8:37–41

    Article  PubMed  CAS  Google Scholar 

  23. Andersen JR, Kristensen JK (1994) Ureteroscopic management of transitional cell tumors. Scand J Urol Nephrol 28:153–157

    Article  PubMed  CAS  Google Scholar 

  24. Schmeller NT, Hofstetter AG (1989) Laser treatment of ureteral tumors. J Urol 141(4):840–843

    PubMed  CAS  Google Scholar 

  25. Wolf SJ Jr (2009) Are we underutilizing minimally invasive approaches for upper tract urothelial carcinoma? Urol Oncol 27(1):75–80

    Article  PubMed  Google Scholar 

  26. Remzi M, Haitel A, Margulis V et al (2009) Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int 103(3):307–311

    Article  PubMed  Google Scholar 

  27. Tavora F, Fajardo DA, Lee TK, Lotan T, Miller JS, Miyamoto H, Epstein JI (2009) Small endoscopic biopsies of the ureter and renal pelvis: pathologic pitfalls. Am J Surg Pathol 33(10):1540–1546

    Article  PubMed  Google Scholar 

  28. Roupret M, Traxer O, Tligui M et al (2007) Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection. Eur Urol 51:709–714

    Article  PubMed  Google Scholar 

  29. Rink M, Fajkovic H, Cha EK, Gupta A, Karakiewicz PI, Chun FK, Lotan Y, Shariat SF (2012) Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol 61(4):854–855

    Article  PubMed  Google Scholar 

  30. Rastinehad AR, Ost MC, Vanderbrink BA, Greenberg KL, El-Hakim A, Marcovich R, Badlani GH, Smith AD (2009) A 20-year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant bacillus Calmette Guérin therapy? Urology 73(1):27–31

    Article  PubMed  Google Scholar 

  31. Palou J, Caparrós J, Orsola A, Xavier B, Vicente J (1995) Transurethral resection of the intramural ureter as the first step of nephroureterectomy. J Urol 154(1):43–44

    Article  PubMed  CAS  Google Scholar 

  32. Goel MC, Mahendra V, Roberts JG (2003) Percutaneous management of renal pelvic urothelial tumors: long-term followup. J Urol 169(3):925–929; discussion 929–930

    Google Scholar 

  33. Clark PE, Streem SB, Geisinger MA (1999) 13-year experience with percutaneous management of upper tract transitional cell carcinoma. J Urol 161(3):772–775; discussion 775–776

    Google Scholar 

  34. Patel A, Soonawalla P, Shepherd SF, Dearnaley DP, Kellett MJ, Woodhouse CR (1996) Long-term outcome after percutaneous treatment of transitional cell carcinoma of the renal pelvis. J Urol 155:868–874

    Article  PubMed  CAS  Google Scholar 

  35. Plancke HR, Strijbos WE, Delaere KP (1995) Percutaneous endoscopic treatment of urothelial tumours of the renal pelvis. Br J Urol 75:736–739

    Article  PubMed  CAS  Google Scholar 

  36. Fuglsig S, Krarup T (1995) Percutaneous nephroscopic resection of renal pelvic tumors. Scand J Urol Nephrol 172:15–17

    CAS  Google Scholar 

  37. Tasca A, Zattoni F, Garbeglio A, Villi G, Bassi P, Meneghini A (1992) Endourologic treatment of transitional cell carcinoma of the upper urinary tract. J Endourol 6:253–256

    Article  Google Scholar 

  38. Raymundo EM, Lipkin ME, Bañez LB, Mancini JG, Zilberman DE, Preminger GM, Inman BA (2011) Third prize: the role of endoscopic nephron-sparing surgery in the management of upper tract urothelial carcinoma. J Endourol 25(3):377–384

    Article  PubMed  Google Scholar 

  39. Thompson RH, Krambeck AE, Lohse CM, Elliott DS, Patterson DE, Blute ML (2008) Elective endoscopic management of transitional cell carcinoma first diagnosed in the upper urinary tract. BJU Int 102(9):1107–1110

    Article  PubMed  Google Scholar 

  40. Suh RS, Faerber GJ, Wolf JS (2003) Predictive factors for applicability and success with endoscopic treatment of upper tract urothelial carcinoma. J Urol 170(6 Pt 1):2209–2216

    Article  PubMed  Google Scholar 

  41. Deligne E, Colombel M, Badet L, Taniere P, Rouviere O, Dubernard JM, Lezrek M, Gelet A, Martin X (2002) Conservative management of upper urinary tract tumors. Eur Urol 42(1):43–48

    Article  PubMed  Google Scholar 

  42. Martínez-Piñeiro JA, García Matres MJ, Martínez-Piñeiro L (1996) Endourological treatment of upper tract urothelial carcinomas: analysis of a series of 59 tumors. J Urol 156(2 Pt 1):377–385

    PubMed  Google Scholar 

  43. Bagley DH, Grasso M (2010) Ureteroscopic laser treatment of upper urinary tract neoplasms. World J Urol 28:143–149

    Article  PubMed  Google Scholar 

  44. Remzi M, Shariat S, Huebner W, Fajkovic H, Seitz C (2011) Upper urinary tract urothelial carcinoma: what have we learned in the last 4 years? Ther Adv Urol 3(2):69–80

    Article  PubMed  Google Scholar 

  45. Remzi M, Javadli E, Özsoy M (2010) Management of small renal masses: a review. World J Urol 28(3):275–281

    Article  PubMed  Google Scholar 

  46. Jeldres C, Lughezzani G, Sun M, Isbarn H, Shariat SF, Budäus L, Lattouf JB, Widmer H, Graefen M, Montorsi F, Perrotte P, Karakiewicz P (2010) Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter. J Urol 183(4):1324–1329

    Article  PubMed  Google Scholar 

  47. Chen GL, Bagley DH (2000) Ureteroscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. J Urol 164:1173–1176

    Article  PubMed  CAS  Google Scholar 

  48. Brown GA, Matin SF, Busby JE et al (2007) Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Urology. 70:252–256

    Article  PubMed  Google Scholar 

  49. Wang JK, Tollefson MK, Krambeck AE, Trost LW, Thompson RH (2012) High Rate of Pathologic Upgrading at Nephroureterectomy for upper tract urothelial carcinoma. Urology 79:615–619

    Google Scholar 

  50. Cutress MLl, Stewart GD, Zakikhani P, Phipps S, Thomas BG, Tolley DA (2012) Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int. doi:10.1111/j.1464-410X.2012.11068.x

  51. Weizer AZ, Faerber GJ, Wolf JS Jr (2007) Progression of disease despite good endoscopic local control of upper tract urothelial carcinoma. Urology 70(3):469–472

    Article  PubMed  Google Scholar 

  52. Xylinas E, Rink M, Cha EK, Clozel T, Lee RK, Fajkovic H, Comploj E, Novara G, Margulis V, Raman JD et al (2012) Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol. doi:10.1016/j.eururo.2012.04.052

  53. O’Brien T, Ray E, Singh R, Coker B, Beard R (2011) Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol 60(4):703–710

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mesut Remzi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fajkovic, H., Klatte, T., Nagele, U. et al. Results and outcomes after endoscopic treatment of upper urinary tract carcinoma: the Austrian experience. World J Urol 31, 37–44 (2013). https://doi.org/10.1007/s00345-012-0948-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-012-0948-4

Keywords

Navigation